Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
23.37
+0.99 (4.42%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Employees
Mineralys Therapeutics had 76 employees as of December 31, 2025. The number of employees increased by 25 or 49.02% compared to the previous year. That makes Mineralys Therapeutics the 32,979th largest employer in the world and 4,307th in the United States.
Employees
76
Change (1Y)
25
Growth (1Y)
49.02%
Revenue / Employee
n/a
Profits / Employee
-$4,599,684
Market Cap
2.07B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 25 | 49.02% |
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Novavax | 749 |
| Agios Pharmaceuticals | 540 |
| Maravai LifeSciences Holdings | 415 |
| Vericel | 398 |
| Vir Biotechnology | 367 |
| Vera Therapeutics | 361 |
| Viridian Therapeutics | 252 |
MLYS News
- 1 day ago - Mineralys Therapeutics presents new analysis from Launch-HTN trial - TheFly
- 1 day ago - Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 - GlobeNewsWire
- 7 days ago - Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 - GlobeNewsWire
- 8 days ago - Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 - GlobeNewsWire
- 10 days ago - Mineralys Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts
- 10 days ago - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewsWire
- 16 days ago - Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 - GlobeNewsWire